Table 1.
Demographics and spondyloarthritis disease characteristics (n=22).
| Parameter | Value, mean (SD) unless indicated otherwise |
|---|---|
|
| |
| Sex (male/female), n (%) | 14 (63.6)/8 (36.4) |
|
| |
| Race, n (%) | |
| Caucasian | 19 (86.36) |
| African | 3 (13.63) |
|
| |
| Age (years) | 38.36 (9.48) |
|
| |
| Duration of inflammatory back pain (years) | 8 (7.18) |
|
| |
| BASFI score | 4.69 (2.30) |
|
| |
| BASDAI score | 4.41 (2.00) |
|
| |
| ASDAS score | 2.51 (0.68) |
|
| |
| C-reactive protein (mg/dL) | 1.59 (2.78) |
|
| |
| Erythrocyte sedimentation rate (mm/h) | 20.16 (21.90) |
|
| |
| Treatment for spondyloarthritis, n (%) | |
| Anti-tumor necrosis factor therapy | 10 (45.45) |
| Methotrexate | 4 (18.18) |
| Non-hormonal anti-inflammatory agents | 4 (18.18) |
| No treatment | 4 (18.18) |
ASDAS, ankylosing spondylitis activity score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; SD, standard deviation.